Issues in the Long-term Management of the Patient With Moderate-to-Severe Crohn's Disease: The Role of TNF Inhibitors CME/CE

Author Information and Disclosures

Release Date: March 31, 2008; Valid for credit through March 31, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.25 nursing contact hours (1.25 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Abbott: No Tagline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the clinical benefits of antitumor necrosis factor (anti-TNF) therapy in the treatment of Crohn's disease
  2. Examine the safety of TNF inhibitors in the induction and maintenance of long-term remission in patients with Crohn's disease
  3. Review clinical data on the benefits of TNF inhibitors in Crohn's disease beyond clinical response and remission: avoidance of hospitalizations and surgery, cost-effectiveness, and quality of life
  4. Discuss the potential benefits of earlier use of anti-TNF therapy for Crohn's disease
  5. Describe approaches to maximize patient adherence and optimize clinical outcomes for patients with Crohn's disease with and without prior exposure to anti-TNF therapy
  6. Recommend a comprehensive management strategy for Crohn's disease
Authors and Disclosures

David T. Rubin, MD
Disclosure: David T. Rubin, MD, has disclosed that he has received grant support from Procter & Gamble, Salix, Prometheus, and Given Imaging. Dr. Rubin has also disclosed that he has served as a consultant to Procter & Gamble, Salix, Prometheus, Abbott Immunology, UCB, Given Imaging, Shire, and Axcan. Dr. Rubin has also disclosed that he has served on the speaker's bureau of Procter & Gamble, Salix, Prometheus, Abbott Immunology, Shire, and Centocor.


Maria Gaiso, PhD
Disclosure: Maria Gaiso, PhD, has disclosed no relevant financial relationships.


Jayashree Gokhale, PhD
Disclosure: Jayashree Gokhale, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.